Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tolerx, GlaxoSmithKline in otelixizumab deal

Tolerx ( Cambridge, Mass.) and GlaxoSmithKline (LSE:GSK; GSK) partnered to develop and commercialize Tolerx's otelixizumab

Read the full 155 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE